GeneTAG Technology, Inc. was founded in 2001 by Dr. David Shafer, a tenured faculty member of Emory University. Our mission is to provide superior molecular detection systems that are precise, simple, and inexpensive. We focus on developing accurate diagnostic qPCR probes for various infectious diseases, cancer-associated somatic mutations, and cellular targets (biomarkers, SNPs, control targets).
GeneTAG has five patents awarded and five patents pending. These patents cover seven novel probe systems for qPCR and liquid biopsy assays, with a focus on sensitive detection of cancer-specific mutations and drug-resistant infectious diseases. GeneTAG has raised $6 million in funding over the years, which has spawned numerous inventions and assays, several of which are being used in patient diagnostics.